Washington University School of Medicine
The investigators hypothesize that zanzalintinib in combination with ipilimumab and nivolumab will be well tolerated and serve as a potential therapeutic strategy in metastatic soft tissue sarcoma (mSTS) including myxofibrosarcoma, undifferentiated pleomorphic sarcoma, dedifferentiated liposarcoma, cutaneous angiosarcoma, and undifferentiated sarcoma histologies.
Inclusion Criteria: * Histologically or cytologically confirmed soft tissue sarcoma that is metastatic or unresectable. * Must have received at least one but no more than 3 lines of therapy in the metastatic setting, with progression on last line of therapy. Neoadjuvant or adjuvant therapy completed more than one year prior does not count towards as a line of therapy in the metastatic. Individuals with alveolar soft part sarcoma may enroll without being refractory to at least one line of therapy. * Measurable disease per RECIST 1.1. * At least 18 years of age. * ECOG performance status ≤ 1. *…
Zanzalintinib will be supplied by Exelixis, Inc.
Ipilimumab will be commercially sourced.
Nivolumab will be commercially sourced.
Arctuva estimate
Verify or correct the compensation shown for this listing.